Table 4. Over-screening and under-screening in the pre-coronavirus disease 2019 (pre-COVID-19) era (n=427^*).

Question number and content†	Categories	n (%)
Q48 Prevalence of over-screening/over-diagnosis/over-treatment of cervical lesions pre-COVID-19	Yes, over-screening	68 (15.9)
	Yes, over-diagnosis	86 (20.1)
	Yes, over-treatment	36 (8.5)
	No	224 (52.5)
	Don’t know	37 (8.7)
Q49 Current delays/cancellations of screening/management procedures have had a positive impact by reducing unnecessary screening/diagnosis/treatment	Yes, over-screening	65 (15.2)
	Yes, over-diagnosis	88 (20.6)
	Yes, over-treatment	45 (10.5)
	No	188 (44.0)
	Don’t know	66 (15.5)
Q50 Prevalence of under-screening/under-diagnosis/under-treatment of cervical lesions pre-COVID-19	Yes, under-screening	161 (37.7)
	Yes, under-diagnosis	127 (29.7)
	Yes, under-treatment	62 (14.5)
	No	109 (25.5)
	Don’t know	54 (12.6)
Q51 Current delays/cancellations of screening/management procedures have had a negative impact by reducing necessary screening/diagnosis/treatment	Yes, under-screening	204 (47.8)
	Yes, under-diagnosis	207 (48.4)
	Yes, under-treatment	129 (25.3)
	No	48 (9.4)
	Don’t know	50 (11.7)

^*Eighty-three respondents did not answer; the total number of complete responses was used as the denominator.

^†Frequency count exceeded number of respondents (427) as some selected more than one answer.